Related Experiment Video
Updated: Sep 6, 2025
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
Rac1 as a Target to Treat Dysfunctions and Cancer of the Bladder
Vincent Sauzeau1, Julien Beignet2, Christian Bailly3
1Université de Nantes, CHU Nantes, CNRS, INSERM, Institut du Thorax, 44202 Nantes, France.
Abstract:
Bladder pathologies, very common in the aged population, have a considerable negative impact on quality of life. Novel targets are needed to design drugs and combinations to treat diseases such as overactive bladder and bladder cancers. A promising new target is the ubiquitous Rho GTPase Rac1, frequently dysregulated and overexpressed in bladder pathologies. We have analyzed the roles of Rac1 in different bladder pathologies, including bacterial infections, diabetes-induced bladder dysfunctions and bladder cancers. The contribution of the Rac1 protein to tumorigenesis, tumor progression, epithelial-mesenchymal transition of bladder cancer cells and their metastasis has been analyzed. Small molecules selectively targeting Rac1 have been discovered or designed, and two of them-NSC23766 and EHT 1864-have revealed activities against bladder cancer. Their mode of interaction with Rac1, at the GTP binding site or the guanine nucleotide exchange factors (GEF) interaction site, is discussed. Our analysis underlines the possibility of targeting Rac1 with small molecules with the objective to combat bladder dysfunctions and to reduce lower urinary tract symptoms. Finally, the interest of a Rac1 inhibitor to treat advanced chemoresistance prostate cancer, while reducing the risk of associated bladder dysfunction, is discussed. There is hope for a better management of bladder pathologies via Rac1-targeted approaches.
Insights
Targeting the Rho GTPase Rac1 offers a new approach for treating bladder pathologies like overactive bladder and cancers. Rac1 inhibitors show promise in managing bladder dysfunction and improving patient quality of life.
Area of Science:
- Urology
- Molecular Biology
- Oncology
Background:
- Bladder pathologies significantly impact the quality of life, especially in the elderly.
- Current treatments for bladder diseases require novel therapeutic targets.
- Rho GTPase Rac1 is frequently dysregulated and overexpressed in various bladder pathologies.
Purpose of the Study:
- To analyze the roles of Rac1 in diverse bladder pathologies, including infections, diabetes-induced dysfunction, and cancers.
- To investigate Rac1's contribution to bladder cancer progression, metastasis, and epithelial-mesenchymal transition.
- To explore the therapeutic potential of small molecule Rac1 inhibitors for bladder diseases.
Main Methods:
- Analysis of Rac1's involvement in tumorigenesis and metastasis of bladder cancer cells.
- Evaluation of small molecules (e.g., NSC23766, EHT 1864) targeting Rac1.
- Discussion of Rac1 inhibitor interaction sites (GTP binding and GEF interaction sites).
Main Results:
- Rac1 plays a significant role in bladder cancer development and progression.
- Specific small molecules targeting Rac1 demonstrate efficacy against bladder cancer.
- Rac1 inhibitors offer a potential strategy for managing bladder dysfunction and lower urinary tract symptoms.
Conclusions:
- Targeting Rac1 with small molecules presents a promising therapeutic avenue for various bladder pathologies.
- Rac1 inhibition may help combat bladder dysfunction, improve symptoms, and treat advanced prostate cancer with reduced bladder side effects.
- Further research into Rac1-targeted approaches could lead to better management of age-related bladder conditions.
More Related Videos
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
08:43An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
Published on: July 28, 2012
Related Concept Videos
02:23Abnormal Proliferation
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:24Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...